Top

Neurological Sciences

Published in:

13-12-2023 | Aura | Original Article

Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study

Authors: Simone Braca, Angelo Miele, Antonio Stornaiuolo, Gennaro Cretella, Roberto De Simone, Cinzia Valeria Russo

Published in: Neurological Sciences | Issue 4/2024

Abstract

Background

About 15% to one third of migraineurs experience aura symptoms. Aura is a reversible focal neurological phenomenon involving visual, sensory, speech, and motor symptoms that usually precede migraine pain. Monoclonal antibodies against calcitonin-related peptide (anti- CGRP mAbs) are effective in preventing chronic and episodic migraine, but little is known about their effectiveness on specifically preventing migraine with aura.

Methods

This is a pilot prospective observational cohort study, aiming at evaluating the effectiveness and safety of Erenumab, Fremanezumab or Galcanezumab for the treatment of migraine aura. We enrolled 14 patients at the Headache Centre of University Federico II of Naples. Duration of follow-up was 12 months. We assessed mean monthly days with aura symptoms, with or without subsequent headache, as well as mean monthly days with headache and mean monthly MIDAS score, by reviewing standardized paper patient headache diaries every three months.

Results

A significant decrease in mean monthly aura days was observed throughout the observation period (median baseline: 13, interquartile range: 4–16; after 12 months: 1, interquartile range: 0–3, p < 0.001). We observed a statistically significant decrease in mean monthly headache days as well (median baseline 21, interquartile range: 16–30; after 12 months: 5, interquartile range: 4–7, p < 0.001). During the 12-month treatment period, none of the 14 patients reported mild or serious adverse events.

Conclusion

Our findings suggest that anti-CGRP mAbs are highly effective in migraine with aura, both in reducing mean monthly aura days and mean monthly days with headache.

Steiner TJ, Stovner LJ, Birbeck GL (2013) Migraine: the seventh disabler. J Headache Pain 14(1):1. https://doi.org/10.1186/1129-2377-14-1

Rasmussen BK, Olesen J (1992) Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia 12(4):221–186. https://doi.org/10.1046/j.1468-2982.1992.1204221.xCrossRefPubMed

Lucas C (2021) Migraine with aura. Rev Neurol 177(7):779–784. https://doi.org/10.1016/j.neurol.2021.07.010

Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S (2017) Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev 97(2):553–622. https://doi.org/10.1152/physrev.00034.2015CrossRefPubMedPubMedCentral

Charles A (2013) Migraine: a brain state. Curr Opin Neurol 26(3):235–239. https://doi.org/10.1097/WCO.0b013e32836085f4CrossRefPubMed

Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ (2011) Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. J Cereb Blood Flow Metab 31(1):17–35. https://doi.org/10.1038/jcbfm.2010.191CrossRefPubMed

Charles A (2018) The pathophysiology of migraine: implications for clinical management. The Lancet Neurology 17(2):174–182. https://doi.org/10.1016/S1474-4422(17)30435-0CrossRefPubMed

Akerman S, Goadsby PJ (2005) Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. NeuroReport 16(12):1383–1387. https://doi.org/10.1097/01.wnr.0000175250.33159.a9CrossRefPubMed

Somjen GG (2001) Mechanisms of spreading depression and hypoxic spreading depression-like depolarization. Physiol Rev 81(3):1065–1096. https://doi.org/10.1152/physrev.2001.81.3.1065CrossRefPubMed

10.

Cozzolino O, Marchese M, Trovato F, Pracucci E, Ratto GM, Buzzi MG, Sicca F, Santorelli FM (2018) Understanding spreading depression from headache to sudden unexpected death. Front Neurol 9:19. https://doi.org/10.3389/fneur.2018.00019CrossRefPubMedPubMedCentral

11.

Mathew AA, Panonnummal R (2022) Cortical spreading depression: culprits and mechanisms. Exp Brain Res 240(3):733–749. https://doi.org/10.1007/s00221-022-06307-9CrossRefPubMed

12.

Edvinsson L (2019) Role of CGRP in migraine. Handb Exp Pharmacol 255:121–130. https://doi.org/10.1007/164_2018_201CrossRefPubMed

13.

Jiang L, Wang Y, Xu Y, Ma D, Wang M (2018) The transient receptor potential ankyrin type 1 plays a critical role in cortical spreading depression. Neuroscience 382:23–34. https://doi.org/10.1016/j.neuroscience.2018.04.025CrossRefPubMed

14.

Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, Bonsi P, Picconi B, Cupini LM, Materazzi S, Geppetti P, Sarchielli P, Calabresi P (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci USA 109(46):18985–18990. https://doi.org/10.1073/pnas.1215435109ADSCrossRefPubMedPubMedCentral

15.

Filiz A, Tepe N, Eftekhari S, Boran HE, Dilekoz E, Edvinsson L, Bolay H (2019) CGRP receptor antagonist MK-8825 attenuates cortical spreading depression induced pain behavior. Cephalalgia 39(3):354–365. https://doi.org/10.1177/0333102417735845CrossRefPubMed

16.

Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39(3):428–434. https://doi.org/10.1177/0333102418774299CrossRefPubMed

17.

Drellia K, Kokoti L, Deligianni CI, Papadopoulos D, Mitsikostas DD (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41(7):851–864. https://doi.org/10.1177/0333102421989601CrossRefPubMed

18.

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d'Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https://doi.org/10.1186/s10194-021-01247-1

19.

Driessen MT, Cohen JM, Thompson SF, Patterson-Lomba O, Seminerio MJ, Carr K, Totev TI, Sun R, Yim E, Mu F, Ayyagari R (2022) Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain 23(1):56. https://doi.org/10.1186/s10194-022-01415-xCrossRefPubMedPubMedCentral

20.

Cullum CK, Do TP, Ashina M, Bendtsen L, Hugger SS, Iljazi A, Gusatovic J, Snellman J, Lopez-Lopez C, Ashina H, Amin FM (2022) Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study. J Headache Pain 23(1):61. https://doi.org/10.1186/s10194-022-01433-9CrossRefPubMedPubMedCentral

21.

Saccà F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R, Russo CV (2023) A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine. Headache 63(6):788–794. https://doi.org/10.1111/head.14528CrossRefPubMed

22.

Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202

23.

Stewart WF, Lipton RB, Dowson AJ, Sawyer J (2001) Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 56(6 Suppl 1):S20–S28. https://doi.org/10.1212/wnl.56.suppl_1.s20CrossRefPubMed

24.

Charles AC, Baca SM (2013) Cortical spreading depression and migraine. Nat Rev Neurol 9(11):637–644. https://doi.org/10.1038/nrneurol.2013.192CrossRefPubMed

25.

Ayata C, Lauritzen M (2015) Spreading depression, spreading depolarizations, and the cerebral vasculature. Physiol Rev 95(3):953–993. https://doi.org/10.1152/physrev.00027.2014CrossRefPubMedPubMedCentral

26.

Shatillo A, Koroleva K, Giniatullina R, Naumenko N, Slastnikova AA, Aliev RR, Bart G, Atalay M, Gu C, Khazipov R, Davletov B, Grohn O, Giniatullin R (2013) Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience 253:341–349. https://doi.org/10.1016/j.neuroscience.2013.09.002CrossRefPubMed

27.

Jiang L, Ma D, Grubb BD, Wang M (2019) ROS/TRPA1/CGRP signaling mediates cortical spreading depression. J Headache Pain 20(1):25. https://doi.org/10.1186/s10194-019-0978-zCrossRefPubMedPubMedCentral

28.

Matteo E, Pensato U, Favoni V, Giannini G, Pierangeli G, Cevoli S (2021) Do anti-CGRP drugs have a role in migraine aura therapy? J Neurol 268(6):2273–2274. https://doi.org/10.1007/s00415-021-10546-1CrossRefPubMed

29.

Albanese M, Mercuri NB (2022) Could the new anti-CGRP monoclonal antibodies be effective in migraine aura? Case reports and literature review. J Clin Med 11(5):1228. https://doi.org/10.3390/jcm11051228CrossRefPubMedPubMedCentral

30.

Al-Khazali HM, Ashina H, Wiggers A, Rose K, Iljazi A, Christensen RH, Schytz HW, Amin FM, Ashina M (2023) Calcitonin gene-related peptide causes migraine aura. J Headache Pain 24(1):124. https://doi.org/10.1186/s10194-023-01656-4CrossRefPubMedPubMedCentral

31.

Russo CV, Saccà F, Braca S, Sansone M, Miele A, Stornaiuolo A, De Simone R (2023) Anti-calcitonin gene-related peptide monoclonal antibodies for the treatment of vestibular migraine: A prospective observational cohort study. Cephalalgia 43(4):3331024231161809. https://doi.org/10.1177/03331024231161809CrossRefPubMed

32.

Melo-Carrillo A, Schain AJ, Stratton J, Strassman AM, Burstein R (2020) Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier. Pain 161(5):1037–1043. https://doi.org/10.1097/j.pain.0000000000001791CrossRefPubMedPubMedCentral

Title: Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study
Authors: Simone Braca
Angelo Miele
Antonio Stornaiuolo
Gennaro Cretella
Roberto De Simone
Cinzia Valeria Russo
Publication date: 13-12-2023
Publisher: Springer International Publishing
Keywords: Aura
Migraine
Headache
Erenumab
Fremanezumab
Galcanezumab
Mood Disorders
Affective Disorder
Published in: Neurological Sciences / Issue 4/2024
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-07241-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2024

Progressive multifocal leukoencephalopathy in patients with chronic kidney disease

Perampanel-induced erectile dysfunction

Correction to: Age‑related hearing loss is not linked to cerebrospinal fluid levels of β‑amyloid or p‑tau181

Perspectives on Neuromyelitis Optica Spectrum Disorders, the Narrative Medicine contribution to care

Head-down tilt reduces the heart rate in postural tachycardia syndrome in acute setting: a pilot study

Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis